Immunity War: A Novel Therapy for Lymphoma Using T-cell Bispecific Antibodies

Ajay Prakash; Catherine S Diefenbach

doi:10.1158/1078-0432.CCR-18-1363

Immunity War: A Novel Therapy for Lymphoma Using T-cell Bispecific Antibodies

Clin Cancer Res. 2018 Oct 1;24(19):4631-4632. doi: 10.1158/1078-0432.CCR-18-1363. Epub 2018 Jun 8.

Authors

Ajay Prakash¹, Catherine S Diefenbach²

Affiliations

¹ Department of Hematology-Oncology, NYU Perlmutter Cancer Center, NYU Langone Health, New York, New York.
² Department of Hematology-Oncology, NYU Perlmutter Cancer Center, NYU Langone Health, New York, New York. catherine.diefenbach@nyumc.org.

PMID: 29884742
DOI: 10.1158/1078-0432.CCR-18-1363

Abstract

The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Clin Cancer Res; 24(19); 4631-2. ©2018 AACR See related article by Bacac et al., p. 4785.

Publication types

Comment

MeSH terms

Antibodies, Bispecific*
Antibodies, Monoclonal, Humanized
Hematologic Neoplasms*
Humans
Lymphoma*
Neoplasm Recurrence, Local
T-Lymphocytes

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
obinutuzumab